The Diagnostic Challenge of Rare NSCLC Subtypes and Fusions

Experts address the critical differences between pre-operative biopsies and post-operative surgical specimens for biomarker testing. They confirm that a surgical specimen is far more reliable, as it provides a larger, higher-quality sample, allowing a pathologist to select a more tumor-rich area for analysis. This was key in finally identifying the patient's RET fusion.

The discussion highlights that while significant tumor heterogeneity is less common in untreated patients, it can occur, especially in cases with mixed histology like this one. The panel concludes that in complex cases—particularly for never-smokers with initially negative results—pursuing further testing on the best available tissue is essential. While finding the RET fusion clarifies the optimal targeted therapy path, the low PD-L1 and never-smoker status continue to suggest a limited benefit from immunotherapy, making clinical trials for adjuvant RET inhibitors the most promising future direction.